[Form 4] Protara Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Kanzhun Limited (BZ) – Form 144 filing overview

The notice discloses a proposed sale of 1,984,500 American Depositary Shares (ADS), each ADS representing two Class A ordinary shares. The filer intends to execute the transaction through UBS Financial Services, 11 Madison Ave., New York on or about 30 June 2025. Based on the filing’s stated market price, the block is valued at approximately US$35.9 million.

The issuer reports 913,310,598 ordinary shares outstanding; the proposed sale therefore represents roughly 0.22 % of the ordinary share count (≈0.43 % of the ADS float, given the 2-for-1 ratio). The securities were originally acquired on 20 May 2014 as “Founder Shares” in exchange for services rendered.

Recent insider activity: the same beneficial owner, Techwolf Limited, previously sold 1,921,500 ADS on 1 April 2025 for gross proceeds of US$32.17 million. Adding the new notice, total planned/ completed disposals within three months reach 3.91 million ADS (≈US$68 million).

Form 144 is a notice of intent; it does not guarantee execution, but it signals potential supply and possible insider sentiment. No new capital is issued, so there is no dilution; however, the sales could create an overhang and incremental selling pressure around the proposed date.

Positive

• None.

Negative

• Founder/insider plans to sell 1,984,500 ADS valued at US$35.9 m, adding to a similar sale in April and signalling potential stock overhang.
• Aggregate insider disposals of ~US$68 m within three months may be perceived negatively by investors monitoring management sentiment.

Insights

Equity Market Strategist

TL;DR – Founder intends to sell US$35.9 m in ADS, extending recent insider disposals; modest supply overhang, mildly negative sentiment.

The filing adds to April’s US$32 m block, taking three-month insider sales to nearly US$68 m. While 0.4 % of the ADS float is not large enough to alter fundamentals, continuous founder selling can be interpreted by the market as waning confidence or portfolio diversification. The transaction is routed through UBS and timed for 30 June 2025, giving traders clarity on when supply may hit the tape. Because Form 144 covers affiliates, shares could enter the open market swiftly under Rule 144(b)(2) if volume conditions are met. There is no dilution, but technical pressure and sentiment effects warrant a cautious view.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shefferman Jesse

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2025		G		1,700	D	$0	976,853	D
Common Stock	06/26/2025		G		3,400	D	$0	973,453	D
Common Stock	06/27/2025		G		10,200	D	$0	963,253	D
Common Stock	06/27/2025		G		3,367	D	$0	959,886	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Jesse Shefferman	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Kanzhun (BZ) ADS are slated for sale under this Form 144?

The filer intends to sell 1,984,500 ADS.

What is the approximate market value of the planned sale?

The block is valued at about US$35.9 million as stated in the filing.

When is the proposed sale date for the Kanzhun ADS?

The filer lists an approximate sale date of 30 June 2025.

Who is executing the trade and on which exchange?

The sale will be routed through UBS Financial Services on the Nasdaq.

What percentage of Kanzhun’s outstanding shares does this represent?

It represents roughly 0.22 % of ordinary shares (≈0.43 % of ADS outstanding).

Have there been recent sales by the same insider?

Yes. A 1,921,500 ADS sale occurred on 1 April 2025, generating US$32.17 million in proceeds.